Novartis Ups Ante In Acromegaly Injectables As Oral Contender Emerges
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis gears up to file new injectable pasireotide LAR by the end of 2012 for the niche acromegaly market, ahead of the patent expiration of its blockbuster Sandostatin LAR. But Israeli biotech Chiasma is hoping to deliver an oral option with Octreolin.
You may also be interested in...
Deals Of The Week Wonders: What Does Merck’s Latest Biosimilar Move Really Mean?
Plus a look at Roche/Chiasma, Chiesi/Cornerstone, Eisai/Valeant and more
Roche Buys Rights To Market Chiasma’s Acromegaly Pill Octreolin
Roche is betting Chiasma’s daily oral drug Octreolin will prove a winner for treating orphan disease acromegaly and hopes the Israel-based biotech’s underlying Transient Permeability Enhancer technology can be used to develop other oral drugs that previously were only available by injection.
Pharmacia Somavert Clears FDA For Acromegaly; Liver Testing Recommended
Labeling for Pharmacia's acromegaly treatment Somavert recommends monthly liver function monitoring for the first six months of treatment